Reprocessing of popular vein treatment catheter results in significant cost savings and medical waste reduction for vein practices Nearly 300 clinics have contracted to have their ClosureFAST catheters reprocessed since launch of the service on January 16, 2012
Terumo Interventional Systems, a strategic business unit of Terumo Medical Corporation, a U.S. subsidiary of Terumo Corporation, today announced the completion of U.S. patient enrollment in the Occlusive/Stenotic Peripheral Artery REvascularization StudY (OSPREY) designed to evaluate the safety and effectiveness of the MISAGOT Self-expanding Stent System. OSPREY is a single-arm, multi-center, non-randomized prospective clinical trial for the treatment of atherosclerotic stenoses and occlusions of the superficial femoral artery that included 200 patients in 31 centers in the U.S. and 100 patients in seven centers in Japan.
La Federación Española de Asociaciones de Linfedema (FEDEAL), entidad miembro de COCEMFE, participó en el Congreso que celebró la International Lynphedema Framework en la ciudad francesa de Montpellier los pasados días 27 al 30 de Junio. Durante su ponencia, FEDEAL presentó la situación en nuestro país, a través de un manifiesto que asegura que existen afectados de Linfedema en todas las Comunidades Autónomas que no están diagnosticados o lo son de forma tardía, muchos no reciben una información correcta sobre la enfermedad, hay largas listas de espera o problemas para acceder a un tratamiento intensivo que incluya el necesario mantenimiento, y muchos pacientes se ven forzados a costearse su propia atención médica.
The use of fenestrated stent grafts has been approved by the U.S. Food and Drug Administration (FDA). Vascular surgeons at the Washington University and Barnes-Jewish Heart & Vascular Center are one of few in the country to offer this treatment option for abdominal aortic aneurysm patients.
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that it has received a Notice of Allowance for its patent application for Dissolution of Arterial Plaque. The patent will issue within the next few months when the US Patent Office completes its registration process. This announcement culminates over five years of effort in pursuit of a patent covering the use of hyodeoxycholic acid for atherosclerotic plaque lesions.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO® (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
The US Food and Drug Administration (FDA) has given clearance to r4 Vascular to market its Vector Percutaneous Transluminal Angioplasty (PTA) balloon catheters in 28 sizes. All Vector balloon catheter sizes are rated for up to 30 atmospheres of pressure and are radiopaque when deflated or inflated.
The medium term results of a first-in-man structured registry have shown that Spiral Flow Grafts enhance treatment for patients with peripheral artery disease. The study is due to be published in the October issue of the Annals of Vascular Surgery.
W. L. Gore & Associates, Inc. (Gore) has received CE mark for the 23 mm and 27 mm diameter sizes of the contralateral leg component of the GORE® EXCLUDER® AAA Endoprosthesis for treatment of abdominal aortic aneurysm (AAA). The new diameter devices provide physicians with the ability to repair AAAs in a wider range of anatomies eligible for minimally invasive endovascular AAA repair.
In a recent study it has been found that cholesterol therapy using multiple drugs over an extended period may be more effective than taking a single statin medication. In previous studies the benefits of using a combination of two or three drugs aimed to aggressively lower LDL (bad cholesterol) and raise HDL (good cholesterol) have been mentioned. This is the first one to show long term benefits over a period of 20 years.
Aptus Endosystems has announced closing on US$25 million of equity financing. Synergy Life Science Partners, a new investor, led the round and was joined by existing investors US Venture Partners and Longitude Capital Management. Mudit K Jain, partner at Synergy Life Science Partners will join the company s Board of Directors.
New guidance published on 27 June 2012 by the UK National Institute for Health and Clinical Excellence (NICE) aims to reduce the current high toll of long-term ill health or death caused by venous thromboembolic diseases by clarifying for the first time what combination of tests and treatments results in the most clinically and cost effective diagnosis and management of the conditions.
Flexible Stenting Solutions, Inc. (“FSS”), a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has extended its CE Mark authorized family of peripheral vascular stents to include the FlexStent® Iliac Self Expanding Stent System.
Clinical investigators are for the first time examining the retrograde tibiopedal interventional approach, an endovascular technique that has the potential to reduce the rate of leg amputations by as much as 50% in patients with critical limb ischaemia. Cook Medical is sponsoring the Tibiopedal Access for Crossing Infrainguinal Artery Occlusions study.
Medtronic, Inc. (NYSE: MDT) announced today that a judge in the Eastern District Court of Virginia last week ruled in Medtronic s favor in a patent case brought by W.L Gore & Associates, Inc.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos